<DOC>
	<DOC>NCT01489111</DOC>
	<brief_summary>This trial is conducted globally. The aim of this trial is to evaluate the haemostatic effect of NNC 0129-0000-1003 during surgical procedures in subjects with haemophilia A.</brief_summary>
	<brief_title>Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtained before any trialrelated activities. (Trialrelated activities are any procedure that would not have been performed during normal management of the subject.) Ongoing participation in the pathfinder™2 (NN70883859) or the pathfinderTM 4 (NN70883861) trial and having received greater than or equal to 5 doses of N8GP Undergoing major surgery requiring daily monitoring of FVIII:C (FVIII activity) and wound status for at least 3 days The patient and/or Legally Acceptable Representative (LAR) is capable of assessing a bleeding episode, keeping an eDiary, capable of home treatment of bleeding episodes and otherwise capable of following the trial procedures Known or suspected hypersensitivity to trial product including allergy to hamster protein or related products Previous withdrawal from the pathfinder™2 (NN70883859) or the pathfinderTM 4 (NN70883861) trial after administration of trial product, except interruption due to inclusion in this pathfinderTM 3 trial (NN70883860) The receipt of any investigational medicinal product (except N8GP) within 30 days prior to enrolment into the trial. (For Brazil, only: Participation in a previous clinical trial within one year prior to screening for this trial (Visit 1), unless there is a direct benefit to the research subject, at the Investigator's discretion) FVIII inhibitors at least 0.6 BU (Bethesda Units)/mL at screening Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records) Immune modulating or chemotherapeutic medication Any disease (liver, kidney, inflammatory and mental disorders included) or condition which, according to the Investigator's judgement, could imply a potential hazard to the patient, interfere with trial participation or trial outcome Unwillingness, language or other barriers precluding adequate understanding and/or cooperation</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>